SequelSEC

MACROGENICS INC MGNX

Pharmaceutical Preparations · CIK 0001125345 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$167.67M
Fiscal year ended 2026-06-30
Operating income
-$40.75M
Fiscal year ended 2026-06-30
Free cash flow
-$65.54M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$73.90MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.16Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin100.0%97th
SBC / revenue9.6%34th
Operating margin-48.7%65th
Current ratio5.10x60th
Net margin-49.9%60th
Revenue YoY growth-0.3%42th
R&D / revenue98.4%43th
CapEx / revenue1.3%43th
FCF margin-55.5%54th

MACROGENICS INC (MGNX) reported revenue of $167.67M and net income of -$14.59M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from MACROGENICS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

MACROGENICS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$167.67M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$40.75M
Net income-$14.59M
Research & development$140.44M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$36.75M
Selling & marketingUnavailable

Balance

MACROGENICS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$113.91M
Total assets$345.41M
Current assets$321.69M
Total liabilities$302.54M
Current liabilities$108.82M
Total equity incl. NCI$42.87M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$24.60M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$3.44M

Cash flow

MACROGENICS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$63.72M
Capital expenditures$1.82M
Investing cash flow-$13.08M
Financing cash flow$60.02M
Net change in cash-$16.78M
Stock-based compensation$10.83M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$5.89M

Derived

MACROGENICS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$65.54M
Gross marginUnavailable
Operating margin-24.3%
FCF margin-39.1%
SBC / revenue6.5%
Current ratio2.96x
Revenue YoY growth11.7%
Net margin-8.7%
R&D / revenue83.8%
CapEx / revenue1.1%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MGNX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.